Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BBI Solutions to showcase reagent development and next generation lateral flow capabilities at AACC 2018

BBI Solutions
Posted on: 30 Jul 18
BBI Solutions to showcase reagent development and next generation lateral flow capabilities at AACC 2018

Leading immunoassay specialist, BBI Solutions, will demonstrate expanded reagent development and manufacturing capabilities and explore the future of lateral flow technology at the world’s largest laboratory medicine tradeshow, AACC, later this month.

The business will showcase its comprehensive combination of reagents and proprietary technology during the annual AACC Clinical Lab Expo, which runs from 31st July – 2nd August in Chicago.

BBI’s innovative lateral flow solution support clients all the way from antibody development to mobile diagnostic reader app provided by BBI’s mobile arm, Novarum DX. The company is one of the first in the diagnostics market to offer this inclusive solution, which encompasses the full product journey, in house.

In addition, BBI continues to use internal development and manufacturing capabilities to expand the company’s reagent offering with the security of supply that diagnostic customers expect and rely on.  Some of those new key products on display at AACC will be the company’s brand-new HIV p24 antibodies and recombinant antigen, an expanded panel of Norovirus antibodies, Cancer antigens, D-dimer, Troponin, and many more. 

The 11-strong delegation representing BBI Solutions will join global leaders in clinical chemistry, molecular diagnostics, lab management and other areas of breaking science in laboratory medicine to network and explore some of the industry’s latest technological advances.

The company will demonstrate its approach, which now comprises all aspects of immunoassay development - namely feasibility and planning, reagent supply and manufacturing, custom antibody development, custom conjugations, lateral flow development and manufacturing, and finally, Novarum DX’s smartphone reader capability which enables immediate, point of care diagnosis.

The company will also demonstrate how goal driven antibody development ensures that the best reagents are combined with performance boosting Morffi™ signal enhancement technology, transforming the diagnostic landscape and meeting even the most challenging sensitivity and specificity goals.  

BBI’s mobile arm, Novarum DX, then provides the final element of the product journey – with its easy-to-use mobile app enabling rapid point of care testing, with just a mobile phone. Novarum’s technology accurately interprets the results of lateral flow assays whilst offering test choreography and tracking disease outbreaks, which provides clients with a competitive advantage within the diagnostic landscape.

Liam Taylor, global sales director of BBI Solutions, said: “We’re very excited to be showcasing at this year’s AACC expo, which is one of the biggest events in the laboratory medicine industry. Our delegation of experts will be promoting BBI Solutions’ powerful, comprehensive service offering, reagents supply and manufacturing ability. BBI Solutions is well positioned to empower customers to achieve all their assay goals through just one company.”

“This combined product and service portfolio provides our clients with a key advantage over competitors, creating a total partnership solution that has the potential to reshape the future of lateral flow and the wider diagnostics landscape. We’re looking forward to joining some of the industry’s biggest names at the tradeshow and promoting BBI Solutions’ exciting proposition on a global stage.”

For more information:

Editor's Details

Steph Bocking

Last updated on: 30/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.